Journal of medical case reports · 2026
Newly diagnosed high-risk localized prostate cancer after multiple [177Lu]Lu-PSMA radioligand therapy in the context of metastatic parotid carcinoma: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Orf Christopher, Handke Analena Elisa, Noldus Joachim, Roghmann Florian, Dellino Martina, Tully Karl H
Аннотация
BACKGROUND: Prostate-specific membrane antigen-direct radioligand therapy (PSMA RLT) is primarily used to treat castration-resistant metastatic prostate cancer (PCa) after prior treatment options have been exhausted. Occasionally, other tumor entities, such as parotid carcinoma in this case, also express prostate-specific membrane antigen (PSMA) on their cell surface.
CASE DESCRIPTION: We present the case of a white 67-year-old patient newly diagnosed with locally advanced PCa despite multiple cycles of Lutetium-177-labeled prostate-specific membrane antigen radioligand therapy ([177Lu]Lu-PSMA-RLT), which he had received for metastatic parotid carcinoma. Interestingly, no regressive histopathological changes were found in the prostate biopsy specimen, despite given PSMA-expression in the prostate.
CONCLUSION: The potential selection of high-grade disease, which appears to have occurred in this patient, underscores the need for further large-scale histopathological examination and thorough follow-up of the current investigational approaches using [177Lu]Lu-PSMA-RLT in high-risk prostate cancer (PCa).
CASE DESCRIPTION: We present the case of a white 67-year-old patient newly diagnosed with locally advanced PCa despite multiple cycles of Lutetium-177-labeled prostate-specific membrane antigen radioligand therapy ([177Lu]Lu-PSMA-RLT), which he had received for metastatic parotid carcinoma. Interestingly, no regressive histopathological changes were found in the prostate biopsy specimen, despite given PSMA-expression in the prostate.
CONCLUSION: The potential selection of high-grade disease, which appears to have occurred in this patient, underscores the need for further large-scale histopathological examination and thorough follow-up of the current investigational approaches using [177Lu]Lu-PSMA-RLT in high-risk prostate cancer (PCa).